Technology

Our human Cell BioEngineMAP™ and BioEngineAI™ technology platform leverages discovery of functionally discrete single cells and precise control over the development process from lab-grown stem cells.

3 KEY CHALLENGES WITH CURRENT CELL THERAPY MANUFACTURING

Unhealthy autologous patient cells yields poor quality of raw source material.

Focusing on cell type doesn’t capture rare cell subtypes affecting desired potency.

Lower rate of cell expansion limits manufacturing scale adding to high costs.

OUR VERSATILE PLATFORM

Enabling Exponential Expansion of Human Stem Cells

The technology platform harnesses the incredible potential of allogeneic umbilical cord derived blood stem cells as a starting source of healthy donor cells to further expand and manufacture potent stem cells for clinical use, while maintaining its stemness.

Enabling Large Scale Differentiation of Rare Immune Cells

The technology platform achieves controlled and well-characterized differentiation process by mimicking developmental process of blood formation in a dish to produce a broad arsenal of rare re-programmable immune cell types.

Platform Differentiation

Begins with healthy cord blood donor stem cells
Manufacturing process enriches most potent cell phenotype
Our novel approach does not require gene editing
Off-the-shelf approach for rapid delivery within days
Scalable manufacturing of multiple doses from one cord blood unit
High tolerability and persistence of cells

Mapping the tumor microenvironment by single-cell genomics to reveal specialized population of immune cells amenable to therapeutic intervention.

Vishwakarma et al, Nature Communications Biology (2021)

Disruptive CGT technology assets under management

"We leverage the natural developmental biology of cells for large scale manufacturing. Each cord unit allows 10-100’s of doses per manufacturing run providing unparalleled scalability" - Founder & CEO

Learn more